U.S. Consumer Finance Stock News

Long term Treasury yields are grinding higher, borrowing costs are climbing, and suddenly the calm corner of life insurers and annuity providers looks a lot more interesting. When bond markets reset like this, balance sheets built around long duration assets can face real stress or find unexpected advantages, and that gap can matter for your portfolio. This article unpacks that story and walks through three U.S. life insurer stocks that appear closely tied to this rate shock, explaining how...

Inflation is running hotter again, the Fed is leaning toward tighter policy, and rate expectations are shifting fast. That mix can squeeze many growth stories, yet it often opens a window for certain U.S. financial stocks that earn more from higher yields and sturdier balance sheets. This article unpacks how the latest CPI surprise and rate hike odds intersect with that theme and reveals three stocks from the screener exposed to this news. The three stocks below are a sample pulled from a...

Oracle stock inched lower today, slipping about 1.7% to US$150, even as the latest quarter showed the kind of profit power that usually excites growth investors. Traders focused on near term worries. The earnings report pointed to a stronger underlying story. The headline is simple: this was a profit story. Basic earnings per share came in at about US$1.58 for Q1 and net income hit roughly US$4.7b, both higher than the immediately preceding quarter on the reported numbers. The market reaction...

S&P Global (SPGI) is drawing fresh attention as investors weigh its recent share performance against the scale of its information franchise, which generated US$16.1b in revenue and US$4.9b in net income. Recent trading has been choppy for S&P Global, with the share price down 19.9% year to date and the 1-year total shareholder return declining 19.5%. However, the 3-year total shareholder return of 14.6% points to a stronger longer-run outcome than the 5-year figure of 1.5%, which suggests...

Intuitive Machines has delivered a very strong 3 year gain, yet the current checks suggest the stock looks expensive rather than like a clear bargain at today’s price of US$14.62. The share price has climbed 241.6% over 3 years, which puts extra pressure on today’s buyers to justify that move with future execution. A new contract for two IM 300 spacecraft platforms may support long term revenue expectations, while reliance on relatively concentrated space contracts can leave the valuation...

Lumentum Holdings reported strong fourth quarter fiscal 2026 results, with revenue and earnings ahead of expectations, supported by cloud and AI demand, new 1.6T transceiver shipments, and expanding ultra high power laser production. The business is ramping manufacturing capacity and investing in R&D to support anticipated record revenue and margin expansion in the first quarter of fiscal 2027, which indicates a focus on scaling higher value optical products tied to AI and data center...

SS&C Technologies Holdings has rolled out Black Diamond AI, an AI-enabled upgrade to its Black Diamond Wealth Solutions platform that uses in-platform assistance, contextual insights, and natural language data queries, all governed through the SS&C AI Gateway and connected to the WorkHQ orchestration system. The launch highlights how SS&C Technologies Holdings is trying to embed governed AI deeply into advisor workflows, with tools like Black Diamond Assist and Insights aimed at cutting...

Sabra Health Care REIT has delivered a strong run over the past five years, yet current valuation checks suggest the stock now leans expensive rather than a clear bargain. Over the past 5 years, Sabra Health Care REIT has returned about 93%, which puts recent gains front and centre when considering what is already priced in. The real estate trust’s future value can hinge on how reliably its tenants convert rent into cash and on how well its own balance sheet holds up against interest costs...

LightPath Technologies stock dropped almost 5% today, extending a rough month for holders who have already seen about a one third slide over 30 days. The hit comes even as the headline story is blunt but clear. Revenue for fiscal 2026 reached about US$71.7 million and the year finished with a backlog of roughly US$110.9 million, yet the company still reported a net loss near US$20.5 million over the past twelve months. Emotion is reacting to the loss. The more important question is whether...

MSC Industrial Direct (MSM) has reshaped its finance leadership. The company named Robert Kuhns as Executive Vice President and Chief Financial Officer, effective September 14, 2026, replacing interim CFO Greg Clark. At a share price of $120.51, MSC Industrial Direct has delivered a 40.39% year to date share price return and a 36.91% total shareholder return over the past year, which signals strong momentum rather than a short-lived bounce. The stock has also produced a 40.40% total...

Coca-Cola (KO) has become a talking point again after the relaunched Mr. Pibb quickly turned into 2026’s fastest growing soda brand, according to Morning Consult, drawing more attention to the wider beverage portfolio. That Mr. Pibb relaunch is landing at a time when Coca-Cola’s shares have already built strong momentum, with a year to date share price return of 27.73% and a 1-year total shareholder return of 35.49%. This reflects how investors are reassessing both growth potential and...

Shoe Station Group came into this earnings print with a bruised chart and a tired story. The stock had fallen about 27% over the past three months, yet it jumped 3.5% today after the quarterly release. That move sits against a simple reality: revenue slipped to US$284.3m and comparable store sales fell 7.1%, while earnings per share landed at US$0.23. For a footwear retailer that relies on store traffic and full price selling, the key headline today is pressure on the core store base despite...

Planet Fitness shares have dropped sharply year to date, yet both intrinsic value work and market multiples currently point to a stock that screens as cheap rather than expensive. The share price is down 53.8% year to date, which means the market has reset expectations materially even as valuation checks flag potential mispricing. Future cash generation from its largely subscription based franchise model can support value, while any slowdown in member additions or pressure on franchisee...

Enterprise Products Partners has quietly turned a long, strong run in the unit price into a valuation puzzle, with a powerful five year return set against a mixed overall value score and a market multiple that still screens as undervalued. For income focused investors eyeing the partnership today, the key question is whether that combination signals remaining upside or simply reflects the risk profile and cash flow profile already on display. Over the past 5 years, Enterprise Products...

IRADIMED has delivered a strong 5 year share price run, yet its current valuation checks suggest the stock now trades at a premium to what its cash flow and market multiples imply. The share price is up about 156.7% over 5 years, which sets a high bar for any new investor looking for further gains from here. The business model, built around MRI compatible patient monitoring equipment, can support expectations for steady cash generation. However, any slowdown in unit demand or pricing could...

Kosmos Energy (KOS) has drawn attention after recent trading action, with the share price closing at US$3.02. Investors are weighing the company’s offshore exposure and current valuation metrics against its recent return profile. The recent 20.32% 1 month share price return and 8.63% 7 day move suggest short term momentum is building in Kosmos Energy, although the 3 year total shareholder return decline of 57.94% contrasts with a 24.28% gain over five years, underscoring a mixed longer term...

Hamilton Lane stock has fallen sharply over the past year, yet the valuation checks paint a more mixed picture that does not clearly tag the shares as either a bargain or obviously expensive. For investors, the recent slide raises the question of whether the current price fairly reflects the business or leans too pessimistic. Over the past 12 months, Hamilton Lane has declined 34.2%, which puts recent sentiment under pressure despite longer term gains over 3 and 5 years. Earnings power tied...

Ionis Pharmaceuticals (IONS) is back in focus after mixed trial and regulatory headlines. Partner Novartis reported that the pelacarsen Lp(a)HORIZON Phase 3 trial did not meet its primary endpoint, while Ionis secured FDA approval for rare disease therapy ZANVASTRO. At a share price of $54.21, Ionis Pharmaceuticals has seen momentum cool, with the stock down 26.02% on a 90 day share price return and the 1 year total shareholder return also lower, despite multi year total returns still...

Iovance Biotherapeutics (IOVA) is set to present at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. This event will give investors fresh commentary to weigh against the stock’s recent performance. Iovance Biotherapeutics has seen sharp swings recently, with the share price falling 3.44% over the last day and 6.44% over the week, while recording a 223.02% year-to-date share price return and a 236.36% total shareholder return over one year. This performance may be...

Centrus Energy stock has delivered a very strong 314.2% gain over the past 5 years, yet on broad valuation checks it now screens as expensive rather than a clear bargain. After a sharp pullback this year, the key issue for investors is whether that earlier run still reflects the fundamentals or whether expectations have moved ahead of what the business can reasonably justify. A 314.2% return over 5 years highlights how powerful the long term move in Centrus Energy has been, even with the...

CoreWeave stock has had a difficult year, with the share price down 20.5% over the past 12 months even as some valuation checks still flag it as undervalued on market multiples. At the same time, a low overall value score suggests the broader set of indicators does not yet point to a clear bargain. The 1 year return has declined 20.5%, which signals that investors who bought a year ago are sitting on sizeable paper losses. New AI cloud projects such as Physical AI Field Engineering and the...

Homes.com survey puts consumer behavior in focus for CoStar Group stock A new Homes.com survey from CoStar Group (CSGP) on new construction buyers shows shoppers coming to the market more informed, expecting larger properties, and emphasizing long term financial confidence and customization. Recent trading has been rough for CoStar Group, with the share price down 6.9% over the past week and roughly 55.1% lower year to date, while the 1 year total shareholder return has fallen 66.1%. This...

Eisai and Biogen (BIIB) just cleared a key hurdle in Canada, with the national drug agency issuing a final recommendation supporting public reimbursement for Alzheimer’s therapy LEQEMBI for eligible early stage patients. For investors, the LEQEMBI update comes at a time when Biogen’s momentum has been rebuilding, with a 1-day share price return of 2.23% and a year-to-date share price return of 21.15%, while the 1-year total shareholder return of 44.74% contrasts with declines in the 3- and...

Inflation is still running hot, gasoline prices are climbing and oil back above $100 is putting fresh pressure on the Federal Reserve ahead of its September meeting. That mix can reshuffle which U.S. energy stocks investors pay attention to and which get left behind. This article walks through three stocks from our U.S. Energy Sector Stocks screener that appear especially exposed to these developments and explains why their next moves could matter for a diversified portfolio. The three stocks...